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Abstract
Background: Chronic immune thrombocytopenia (ITP) is a debilitating autoimmune disorder that causes a
reduction in blood platelets and increased risk of bleeding. ITP is currently managed with various pharmacologic
therapies and splenectomy.
This study was conducted to assess patient perceived and reported treatment side effects, as well as the perceived
burden or bother, and need to reduce or stop treatment, associated with these side effects among adult patients
with chronic ITP.
Methods: A Web-enabled survey was administered to members of a US-based ITP patient support group. Patients
reported demographic and clinical characteristics, ITP treatments’ side effects for treatments received since
diagnosed, level of bother (or distress), and need to reduce or stop treatment, associated with side effects. Current
and past exposure was assessed for five specific treatment types: corticosteroids (CS), intravenous immunoglobulin
(IVIg), anti-D immunoglobulin (anti-D), rituximab (RT), and splenectomy (SPL), as well as for other patient-referenced
therapies (captured as “other”).
Results: The survey was completed by 589 patients; 78% female, 89% white, mean age 48 years (SD = 14.71), and
68% reported a typical low platelet count of < 50,000/μL. Current or past treatment with CS was reported by 92%
(n = 542) of patients, 56% (n = 322) for IVIg, 36% (n = 209) for anti-D, 36% (n = 213) for RT, and 39% (n = 227) for
SPL. A substantial proportion of CS-treated patients reported side effects (98%, P < 0.05), were highly bothered by
their side effects (53.1%, P < 0.05), and reported the need to stop or reduce treatment due to side effects (37.8%,
P < 0.05). Among patients reporting side effects of treatment, significant associations were noted for the number
of side effects, aggregate bother of reported side effects, and the need to stop or reduce treatment (all P < 0.05).
Conclusions: Current ITP treatments, particularly corticosteroids, are associated with multiple bothersome side
effects that may lead to patients stopping or reducing therapy. Open, informed and complete communication
between clinician and patient regarding both the benefits and the side effects of ITP treatment may better prepare
patients for their prescribed regimens.
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Background
Immune thrombocytopenia (ITP) is an autoimmune dis-
order characterized by increased platelet destruction and
suboptimal platelet production, resulting in a decreased
number of circulating platelets and increased incidence
of bleeding [1,2]. The most common symptoms of ITP
are mild bruising and mucosal bleeding; however, some
ITP patients experience life-threatening epistaxis,
menorrhagia, gastrointestinal bleeding, and central ner-
vous system bleeding [3]. In the United States, chronic
adult ITP occurs at a prevalence of 9.5-20 per 100,000
persons [4,5]. Although the mortality rate is fairly low in
adults (< 1%) under the age of 65 [6]. morbidity
increases in older individuals due to age-related spikes
in spontaneous bleeding events [7]. and post-splenect-
omy (SPL) complications [8].
The goal of ITP therapy is to prevent major bleeding.
ITP treatment usually consists of corticosteroids (CS) as
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any medium, provided the original work is properly cited.a first-line approach [9]. Patients intolerant or with con-
traindications to steroids, are treated with intravenous
immunoglobulin (IVIg), and anti-D immunoglobulin
(anti-D) [10], either alone or in combination [11]. SPL is
frequently recommended as a second-line therapy and
results in sustained remission for nearly two-thirds of
treated patients [1,12]. Approximately 35-40% of chronic
ITP patients are refractory or unresponsive to CS,
immunoglobulins, and SPL [1]. For refractory patients,
therapeutic options are limited and morbidity increases
substantially [7]. Although ITP is not a labeled indica-
tion for rituximab (RT), this monoclonal antibody ther-
apy has become an alternative for chronic ITP patients
refractory to initial treatments [6]. Complete disease
remission has been documented in 25-50% of patients
treated with RT, with some patients remaining in remis-
sion for more than one year [6,13].
However, safety concerns have also been noted [11,14].
Although standard and emerging therapies have reduced
the risk of bleeding among chronic ITP patients, treat-
ments are associated with side effects that may impose
substantial burden on patients. The negative effects of
long-term CS use have been documented to include dia-
betes, hypertension, osteoporosis, mood swings, insomnia,
weight gain, and increased susceptibility to infection [15].
Clinical trials suggest that IVIg is associated with head-
ache, fever, myalgia, and other immediate effects (as well
as rare late effects), while anti-D is associated with chills,
pyrexia, increase in bilirubin, and headaches [16,17]. An
increased risk of incision site infection and up to one per-
cent chance of post-surgical death from sepsis has been
observed among patients undergoing SPL [12,18]. Adverse
effects associated with RT infusions include increased sus-
ceptibility to infections, progressive multifocal leukoence-
phalopathy, chills, fever, severe anaphylactoid reactions,
and death [6,19].
Although these ITP-treatment-related side effects have
been noted, no studies have quantitatively assessed
patient-reported ITP treatment side effects along with the
real-world burden (i.e., bother or distress) associated with
them, or attempted to determine whether their impact is
associated with patients reducing or stopping treatment.
More generally, few studies have assessed patient percep-
tion of ITP therapy and implications for health-related
quality of life (HRQL). In one study, Mathias and collea-
gues [20] developed and validated an instrument to assess
the impact of ITP and ITP therapies on patient HRQL.
The authors concluded that the symptoms of ITP and side
effects of various therapies can have a significant negative
impact on patient HRQL [21]. A more thorough under-
standing of patient perception of treatment side effects
can contribute to more effective clinician-patient commu-
nications on the advantages and disadvantages of specific
regimens, so that patients can be more informed as they
embark on their regimen.
Therefore, to understand t h en a t u r eo fp a t i e n tp e r -
ceived chronic ITP treatment side effects, the burden
that adult patients associate with them, and their possi-
ble impact on the reduction or stopping of treatment,
we designed and administered a survey to adults with
chronic ITP.
Methods
Study sample
Study participants were comprised of self-identified adult
patients with chronic ITP from among the membership of
the Platelet Disorder Support Association (PDSA), a
patient support group in the United States. Eligible study
patients met the following criteria: diagnosed with chronic
ITP, 18 years of age and older, and past or current experi-
ence with one or more of the most frequently used ITP
treatment types: CS, IVIg, anti-D, RT, or SPL.
Survey instrument development
Accepted procedures were used to develop and field the
survey instrument [22-24]. To draft the initial version, we
identified ITP treatment side effects from product litera-
ture and package inserts, a review of the published medical
literature, and expert clinical opinion. Upon central insti-
tutional review board approval, two patient focus groups
with four and seven adults respectively with chronic ITP
who met the eligibility criteria stated above, were con-
ducted at the 2008 PDSA annual conference. The feedback
of these patient focus groups was used to finalize the list of
treatment side effects from the patient perspective and to
ensure the clarity and accuracy of the instrument. Finally
patient cognitive testing was implemented via phone inter-
views with three adult patients. These patients simulta-
n e o u s l yc o m p l e t e dt h eo n l i n es u r v e yw h i l ep r o v i d i n g
feedback to a trained interviewer on ease of use, clarity,
and acceptance of survey content and instructions.
Survey instrument
The survey instrument was specifically designed to col-
lect patient self-reported data via a secure Internet portal
on: (1) the types and numbers of side effects experienced
during past and current treatments; (2) the level of bur-
den, alternatively known as “bother” [25] or “distress”,
that patients’ experienced with each reported side effect;
and, (3) the patient-perceived impacts or limitations of
their disease and its treatments on current daily function-
ing and treatment continuation. “Bother” is a term com-
mon among clinical researchers focused on patient
health-related quality of life. Specifically, it refers to the
amount of interference or negative impact an effect or
condition has on a patient’sw e l l - b e i n g .“Aggregate
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across all experienced effects among patients in receipt of
the therapy of interest.
The instrument included modules for each treatment
class: CS, IVIg, anti-D, RT, and SPL and an ‘Other’ inter-
vention category. As part of the automatic navigation of
the web-enabled survey, patients were allowed to com-
p l e t eo n l yt h em o d u l e sf o rt h et r e a t m e n t sw i t hw h i c h
they had experience. Each treatment module included
questions on treatment effects and associated bother for
each treatment effect, as well as questions relating to
duration of treatment, time since last treatment, and
whether or not the patient had to stop or reduce treat-
ment due to one or more of the reported side effects.
Three questions related to patient perceived impact of
disease on daily life. Several questions addressed clinical
characteristics (e.g., typical low and high platelet count in
the past 12 months), symptoms (e.g., wet bleeds (nose or
mouth bleeds) and dry bleeds (bruising, hematomas, or
petechiae) in the past 12 months), and demographic
information.
Treatment side effects, if any, were ascertained via a ser-
ies of closed ended questions, along with an open-ended
option to document an “other” effect, which the patient
then listed. Patients could specify a treatment effect that
w a sn o tl i s t e do rc o u l dr e s p o n dt h a tn ot r e a t m e n ts i d e
effects were experienced. For each selected treatment
effect, the automated web-survey allowed patients to indi-
cate their level of bother or distress for that effect, using a
standard 5-point, fully anchored, Likert scale [25] (1 =
“N o tb o t h e r e da ta l l ; ” 2=“Bothered a little bit;” 3=“Mod-
erately bothered;” 4=“Bothered quite a bit;” and 5 =
“Extremely bothered”). To assess perceived impact of dis-
ease on daily life, patients were asked; “How much does
your chronic ITP limit you in your: (a) choice of occupa-
tion or job, (b) daily activities, and (c) lifestyle.” Again,
with a standard 5-point, fully anchored Likert scale [26],
patients rated their limitation due to disease in one of the
following response categories: 1 = “Not limiting at all;” 2=
“Limiting a little bit;” 3=“Moderately limiting;” 4=“Lim-
iting quite a bit;” and 5 = “Extremely limiting.”
Data collection
Upon study approval from the Abt Associates Institu-
tional Review Board, a registered central institutional
review board, and in accordance with the Declaration of
Helsinki, accepted research practice [22,24], and local
laws and regulations, the instrument was fielded among
patients with chronic ITP. First, patients in the PDSA
were presented with an open invitation to participate. If
interested, they then provided online consent as part of
the web-based survey, before participating in the web-
b a s e ds u r v e yd a t ac o l l e c t i o n .T h es u r v e yw a sc o n d u c t e d
via an Internet portal with appropriate security. To
control access to the survey and ensure patient confiden-
tiality, each survey invitation included a unique pass-
word-protected link. A small honorarium ($20 USD) was
provided to each qualifying patient completing the sur-
vey. To ensure complete data, the survey was configured
to require an appropriate response to each relevant ques-
tion before proceeding to the next question or step in the
survey.
Statistical methods
Descriptive analyses and independent t-tests comparing
means were conducted. Ordinary Least Squares (OLS)
and logistic regression analyses were performed to assess
the association with aggregate bother, the need to stop or
reduce treatment, and limitation on daily life. Models to
evaluate the impact of effects on the need to stop or
reduce treatment included the number of side effects and
aggregate bother as the independent variables and the
need to stop or reduce the dose (yes/no) as the depen-
dent variable. Given that each patient had experience
with a different combination of treatment types, a term
was created to account for all patients in the model asses-
sing limitation to daily life (treatment exposure (0,1) ×
Aggregate Bother (1-5)). Aggregate Bother was defined as
a per patient weighted average of bother scores across
their perceived side effects. Perceived impact or limita-
tions imposed by chronic ITP on occupation, daily activ-
ities, and lifestyle were each assessed using OLS
regression models which included terms for aggregate
bother per side effect per treatment (0 = no treatment
and 1-5 = bother). For all analyses, two-sided alpha levels
of P < 0.05 were considered statistically significant. SAS
9.0 was used for analysis.
Results
The survey was completed by 589 qualifying chronic ITP
patients. All surveys were submitted by respondents with
no missing data (consistent with the design of the web
survey), and all completed surveys were able to be
analyzed.
Patient demographic and clinical characteristics
Table 1 shows patient demographic and clinical charac-
teristics. Of the 589 patients completing surveys, 78%
were female, 89% white, and the mean age was 48 years
(SD = 14.71). A majority (59%) had been initially diag-
nosed 5 or more years previously. While 68% of patients
reporting a typical low platelet count below 50,000 /μL
in the past 12 months, 54% of patients experienced
bleeds at a platelet count less than 25,000 /μL. Most
(90%) of patients started taking their medication when
their platelet counts decreased below 50,000 /μL, and
56% of patients did not exceed a high platelet count
greater than 150,000 /μL.
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Patients with current or past CS exposure reported
experiencing significantly more treatment side effects
with CS exposure than associated with the other four
therapies (P < 0.05). CS users reported a mean (SD) of
10.7 (5.7) treatment effects, IVIg users had 2.3 (2.2), anti-
D patients had 2.4 (2.2), RT patients had 2.1 (2.2), and
patients who had received a SPL reported 1.5 (1.2)
effects. Fewer patients withC Se x p e r i e n c er e p o r t e dn o
treatment side effects (2%) compared to the other treat-
ment types (P < 0.05) ranging from 22% to 27%. As
shown in Figure 1, stopping or reducing therapeutic dose
(37.8%) was associated with the side effect experience of
CS therapy, compared to other types of treatment (IVIg,
18.0%; anti-D, 20.6%; RT, 16.4%. All P <0 . 0 5 ) .Ah i g h
level of burden or bother (4 = “Bothered quite a bit;” or 5
= “Extremely bothered”) for one or more side effects of
therapy (53.1%) was associated with CS exposure com-
pared to other treatment types (Additional file 1).
Bother associated with treatment effects
This study reported the number of side effects asso-
ciated with therapy, the mean bother or distress for
each side effect, and a mean aggregate bother score. The
Table 1 Patient clinical and demographic information
All patients
n Percentage
Total 589 100%
Demographics
Age (Mean (SD)) 47.74 (14.71)
18-24 32 5.4%
25-34 96 16.3%
35-44 122 20.7%
45-54 134 22.8%
55-64 133 22.6%
65-74 51 8.7%
75+ 21 3.6%
Race/Ethnicity (multiple response)
White, not of Hispanic origin 521 88.5%
Hispanic 27 4.6%
Black, not of Hispanic origin 23 3.9%
Asian or Pacific Islander 12 2.0%
American Indian/Alaskan Native 8 1.4%
Employment
Employed–Full time 284 48.2%
Employed–Part time 77 13.1%
Self-Employed 38 6.5%
Unemployed 190 32.3%
Patient symptoms and clinical characteristics
Wet Bleeds (Nose or mouth bleeds (in past year))
Not at all 317 53.8%
Once or twice 193 32.8%
Once a month or up to 12 times 54 9.2%
More than once a month 25 4.2%
Dry Bleeds (bruising, hematomas, or petechiae (in past year))
Not at all 122 20.7%
Once or twice 149 25.3%
Once a month or up to 12 times 132 22.4%
More than once a month 186 31.6%
Among the patients, 92% (n = 542) had current or past use of CS, 56% (n = 322) IVIg, 36% (n = 209) anti-D, 36% (n = 213) RT, and 39% (n = 227) SPL. Patients
reported current or past experience with a mean 2.58 (SD = 1.17) treatment types among the five alternatives. A mean of 3.12 (SD = 1.83) treatments was
reported across all treatments listed, including Danazol (17%), cyclophosphamide (8%), vinca alkaloids (7%), azathioprine (6%), and cyclosporine (4%).
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effects was highest for CS and included: 82.8% of
patients reporting weight gain or increased appetite;
77.1%, changes in personality, mood, or emotions, and
75.3%, problems sleeping. SPL also had a highly frequent
side effect, scarring from incision (67.4%) with a bother
mean of 2.5 (1.22). All other CS identified side effects
were reported by fewer than 50% of patients. Among
patients who reported one or more treatment effects,
mean aggregate bother for CS (3.73 [0.70]; n = 531) was
significantly higher than that for IVIg (3.56 [1.00]; n =
247), RT (3.46 [1.03]; n = 153) and SPL (2.74 [1.09]; n =
175) (all P < 0.05). The mean aggregate bother for anti-
D (3.60 [0.95]; n = 159), based upon patients with one
or more effects, was not significantly different than that
for CS, although higher than SPL.
Impact of effects and bother on the need to stop or
reduce treatment
Patients who reported one or more side effects were more
likely to stop or reduce treatment if they also reported
higher aggregate bother for that specific treatment. This
was the case for patients undergoing any of the four non-
surgical treatment types: CS: OR 1.88 (95% CI 1.40, 2.53),
n = 531; IVIg: OR 2.48 (95% CI 1.68, 3.64), n = 247; anti-
D: OR 4.21 (95% CI 2.43, 7.31), n = 161; RT: OR 2.88
(95% CI 1.76, 4.72), n = 156. For CS, number of side
effects also was significantly associated with the need to
stop/reduce treatment (OR 1.05, 95% CI 1.01, 1.08).
Determinants of treatment type bother
Table 2 shows the results of five regression models that
were analyzed to better understand factors associated
with aggregate bother among patients with at least one
side effect. The models (except for anti-D) were charac-
terized by low adjusted R
2, suggesting that other factors
not in the models also may have contributed to the
results. The models did include factors that determined
bother, as illustrated by the statistical significance of the
beta estimates. Specifically, higher numbers of side
effects were significantly associated with increased
aggregate bother for all treatment types. The need to
stop or reduce treatment also was significantly asso-
ciated with aggregate botherf o rC S ,I V I g ,a n t i - D ,a n d
RT. For those treated with CS, gender also was asso-
ciated with aggregate bother as female patients reported
higher levels of bother than males.
Determinants of patients’ day-to-day functioning
Greater limitations for occupation, daily activities, and
lifestyle were significantly associated with more frequent
wet bleeds and lower platelet counts. Greater limitations
on daily activities and lifestyle, but not occupation, were
significantly associated with more frequent dry bleeds.
(Table 3)
Discussion
These study findings present new empirical information
on patients’ perspectives of the burden of ITP therapies:
C S ,I V I g ,a n t i - D ,R T ,a n dS P L .M o r et h a nt w o - t h i r d so f
the surveyed ITP patients reported experiencing treatment
side effects, either at present or in the past. There was a
substantial amount of individual patient variation in both
the side effects reported by therapy and the magnitude of
bother or burden of those side effects.
Although patients who used any of the five ITP thera-
pies were highly bothered or distressed by particular side
effects, CS was associated with more side effects and the
highest magnitude of bother. Significantly, the proportion
of patients treated with CS (37.8%) who had to stop or
reduce treatment due to treatment CS side effects was
roughly double the proportion of patients treated with
other therapy types (IVIg, 18.0%; anti-D, 20.6%; RT, 16.4%.
all P < 0.05) reporting having to stop or reduce treatment
due to treatment side effects. The overall burden of CS for
ITP patients is significant, especially given that 90% of sur-
veyed chronic ITP patients received CS as part of their
treatment regimen. The substantial burden of CS is largely
related to the prevalence of associated side effects and the
bother or distress that patients attribute to these side
effects. Although patients rated particular side effects as
highly bothersome within all treatment types, more than
half of patients with CS exposure (53%) reported highly
bothersome side effects compared to the other therapies.
Approximately, 63.7-82.8% of patients were affected by the
five most pervasive and highly bothersome CS side effects.
Due to the retrospective natu r eo ft h i ss t u d y ,d a t aw e r e
98%
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11% 9% 11% 11%
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Figure 1 Reported side effects, highly bothered (% 4-5) and
need to stop or reduce treatment by treatment type (% of
patients in each category).
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and duration of therapy). Research should be conducted
into the particular effects of specific treatment regimens
(e.g., long versus short courses of CS therapy), to deter-
mine (as appropriate) how different doses and durations
may influence the prevalence and bother of side effects in
these patients.
Regression models showed patient aggregate bother
for each of the treatment types to be associated with: (1)
the number of effects experienced and (2) if these effects
contributed to patients having to stop or reduce treat-
ment. This finding suggests that the more side effects
patients experience, the more likely they experience
“bother”,a n dt h em o r el i k e l yt h e ym a yb et os t o po r
reduce treatment. Length of exposure, i.e. duration of
therapy, was not a significant determinant of the bother
associated with CS use.
The bother that patients attributed to each treatment
type depended upon recollection of past and current
treatments. Anti-D was the only treatment type with a
significant association between recall (time since last
treatment) and aggregate bother. Higher levels of anti-D
treatment side effect bother were associated with cur-
rent anti-D treatment, and lower levels of bother were
associated with past treatments. In addition, anti-D was
the only treatment type studied in which its patient-per-
ceived bother was associated with additional factors
than the number of side effects experienced and the
need to stop or reduce treatment. These findings may
be partially explained by patients reporting perceived
greater bother of side effects than they are presently
experiencing. Also specific side effects commonly asso-
ciated with anti-D (i.e., fatigue, pain, and dizziness) may
lend to a greater recall effect–being perceived as more
bothersome in the present, than in the past.
A limitation of the study is its focus on five frequently
used traditional therapies; patients may have chosen
non-traditional therapies to avoid side effects [27]. New
therapies, such as the thrombopoeitin (TPO) receptor
agonists, were only recently approved in the US at the
time of this survey. It may be informative to repeat this
research now that the TPO receptor agonists and
mimetics are more commonly available in clinical prac-
tice. As treatment evolves, it will be important to
Table 2 Regression model predicting aggregate bother among patients with at least one side effect
Independent variables Corticosteroids IVIg Anti-D Rituximab Splenectomy
Group Mean (SD)§§ 3.73 (0.70) 3.56 (1.00) 3.60 (0.95) 3.46 (1.03) 2.74 (1.09)
Adjusted R
2 (N) 0.19 (440) 0.11 (208) 0.32 (128) 0.19 (130) 0.12 (151)
Age 0.03(.00) -0.06(.00) -0.01(.00) -0.13(.01) 0.05(.01)
Frequency of dry bleeds (0 = No bleeds, 1 = bleeds) 0.01(.10) -0.10(.25) 0.24(.26) ** 0.16(.29) -0.03(.25)
Time since diagnosis¶ -0.01 (.05) 0.00(.12) -0.01(.13) 0.07(.17) 0.13(.26)
Gender (0 = Male; 1 = Female) 0.17(.08) **** 0.10(.17) 0.09(.20) 0.06(.21) 0.05(.21)
Longest cycle duration§ -0.07(.04) - - - -
Typical low platelet count (past year) 0.02(.00) 00(0) 0.25(.00) * -0.10(.00) 0.14(.00)
Need to stop or reduce (0 = No, 1 = Yes) 0.15(.06) ** 0.31(.16) **** 0.43(.17) **** 0.34(.21) **** -
Number of treatment effects 0.35(.01) **** 0.15(.04) * 0.24(.04) ** 0.23(.04) ** 0.34(.09) ****
Number of ITP treatments (among 5 treatment -0.04(.02) -0.11(.05) -0.04(.06) 0.09(.07) -0.01(.07)
types)
Other ITP medications in combination (0 = No; 0.08(.07) 0.07(.15) 0.08(.16) 0.00(.18) -
1 = Yes)
Time since last taking drug/procedure† 0.08(.07) -0.02(.15) -0.18(.19) * -0.11(.19) 0.01(.16)
Type of physician‡ -0.06(.09) -0.03(26) 0.11(.27) 0.07(.40) -0.02(.24)
Frequency of wet bleeds (0 = No bleeds, 1 = bleeds) -0.03(.07) 0.07(.15) -0.22(.16) ** -0.16(.20) -0.05(.21)
* P< 0.05
** P< 0.01
** * P< 0.001
** * * P< 0.0001
Each model based on patients reporting 1 or more side effect.
† Categorical variable were 0 = Currently taking (Less than 5 years ago in case of splenectomy), 1 = Taken in the past (5 or more years ago in case of
splenectomy)
‡ Type of physician referred to generalist or specialist.
¶ Categorical variable were 1 = 6 months to 1 year ago, 2 = 1 to 5 years ago, 3 = 5 or more years ago.
§ Categorical variable were 1 = Less than 1 month, 2 = 1 to 3 months, 3 = 3 to 12 months, 4 = more than 12 months.
§§ Mean based only on patients who reported 1or more treatment effects for a given treatment type. (i.e., coding of 1 for patients with no side effects was not
used).
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A l s o ,i ti sn o tk n o w nw h e t h e rt h es a m p l eo fP D S A
members is representative of chronic ITP patients in the
community. Although the demographic and clinical
characteristics of these patients are similar to those
observed in recent publications and consistent with
those expected for patients with chronic ITP [3,29],
replicating this study in other cohorts would be valu-
able. Finally, this prospective patient-reported outcomes
study depended on patient recall, which may not be as
accurate as direct, coincident to therapy, measurement.
However, the large sample size and the complementarity
of the reported findings provide an indication of the
robust nature of the results.
Conclusions
In conclusion, side effects and associated bother may
lead to reductions in treatment adherence and limita-
tions in daily functioning. The burden of CS is especially
high, with more than four times the percentage of
patients reporting highly bothersome side effects com-
pared to other treatment types, and double the percen-
tage of patients reducing or stopping treatment as a
result. Open communication between clinician and
patient regarding ITP treatment side effects as well as
benefits can help patients become aware of what effects
may be experienced on treatment, so that ultimately
adherence may be improved.
Additional material
Additional file 1: Appendix Table for Editorial Review–Treatment
side effects and bother.
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